- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06918561
Avaliando a eficácia do neotelium ft no tratamento de feridas abertas crônicas
Avaliação da eficácia do Neotelium ft na cura de feridas abertas crônicas: um estudo multicêntrico controlado randomizado
This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet the study requirements during screening will be randomly assigned to one of two groups: either standard of care (SOC) alone, or SOC plus NeoThelium FT.
The study includes a crossover component for subjects in the SOC arm. At treatment visit 13 (approximately 84 days post-randomization), SOC arm subjects not having achieved complete wound closure, and still meeting the inclusion/exclusion criteria, are eligible to cross over to the IP arm (SOC plus NeoThelium FT). Crossover subjects will begin IP arm treatment with weekly NeoThelium FT applications for up to 12 treatment visits. The subject will continue follow-up per the original schedule. As this is a post-marketing study, it will gather information regarding the efficacy of treatment while also supporting insurance reimbursement decisions. All subjects will complete two-week screening phase prior to being randomized into a treatment arm. Treatment arms will consist of NeoThelium FT in conjunction with standard of care, vs. standard of care alone. The primary endpoint will be the percentage of target ulcers that achieve complete wound closure within 12 weeks. Secondary endpoints consist of wound percentage area reduction rates and pain assessment.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Angelina Ferguson, DNP
- Número de telefone: (985) 629-4013
- E-mail: info@sygnola.com
Estude backup de contato
- Nome: Sarah Moore, MBE
- Número de telefone: (985) 629-4013
- E-mail: info@sygnola.com
Locais de estudo
-
-
Louisiana
-
Denham Springs, Louisiana, Estados Unidos, 70726
- Recrutamento
- MedCentris of Denham Springs
-
Investigador principal:
- Monique Consoer, NP
-
Contato:
- Tabatha Yent
- E-mail: tabatha.yent@medcentris.com
-
Hammond, Louisiana, Estados Unidos, 70403
- Recrutamento
- MedCentris of Hammond
-
Investigador principal:
- Chris Keaton, NP
-
Contato:
- Chelsea Smith, RN
- E-mail: Chelsea.smith@medcentris.com
-
Contato:
- Melanie Knox, LPN
- E-mail: Melanie.knox@medcentris.com
-
Lafayette, Louisiana, Estados Unidos, 70507
- Concluído
- MedCentris of Carencro
-
Leesville, Louisiana, Estados Unidos, 71146
- Recrutamento
- MedCentris of Leesville
-
Investigador principal:
- Stefanie Corley, FNP
-
Contato:
- Brandi Shuff
- E-mail: Brandi.shuff@medcentris.com
-
Many, Louisiana, Estados Unidos, 71449
- Recrutamento
- MedCentris of Many
-
Investigador principal:
- Stefanie Corley, FNP
-
Contato:
- Brandi Shuff
- E-mail: Brandi.Shuff@medcentris.com
-
Marksville, Louisiana, Estados Unidos, 71351
- Recrutamento
- MedCentris of Marksville
-
Investigador principal:
- Averie Rachal, FNP
-
Contato:
- Laura Whittington
- E-mail: Laura.whittington@medcentris.com
-
Metairie, Louisiana, Estados Unidos, 70001
- Recrutamento
- MedCentris of Metairie
-
Contato:
- Ninya Powell
- E-mail: ninya.powell@medcentris.com
-
Investigador principal:
- Sarah Logrande, NP
-
Minden, Louisiana, Estados Unidos, 71055
- Recrutamento
- MedCentris of Minden
-
Investigador principal:
- Taheera Forbes, NP
-
Contato:
- Brianna Thompas
- E-mail: brianna.thompson@medcentris.com
-
Monroe, Louisiana, Estados Unidos, 71201
- Ainda não está recrutando
- MedCentris of Monroe
-
Investigador principal:
- Libbi Trawick, NP
-
Contato:
- Tiffany Dew
- E-mail: Tiffany.dew@medcentris.com
-
Slidell, Louisiana, Estados Unidos, 70458
- Recrutamento
- MedCentris of Slidell
-
Investigador principal:
- Katie Schloegel, FNP
-
Contato:
- Donyille Singletary, RN
- Número de telefone: 985-602-1215
- E-mail: Donyille.singletary@medcentris.com
-
-
Mississippi
-
D'Iberville, Mississippi, Estados Unidos, 39540
- Concluído
- MedCentris of D'iberville
-
McComb, Mississippi, Estados Unidos, 39648
- Concluído
- MedCentris of McComb
-
Natchez, Mississippi, Estados Unidos, 39120
- Concluído
- MedCentris of Natchez
-
Southaven, Mississippi, Estados Unidos, 38671
- Recrutamento
- MedCentris of Southaven
-
Investigador principal:
- Carlene McAllister, NP
-
Contato:
- De'Nyia Woods
- E-mail: denyia.woods@medcentris.com
-
-
New York
-
Brooklyn, New York, Estados Unidos, 11234
- Recrutamento
- Northeast Podiatry Consultant
-
Contato:
- Thomas Hayes
- E-mail: thomas@simonfootandankle.com
-
Investigador principal:
- David Simon, DPM, FACFAS
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male or Female, 18 years of age or older
- Subject has a medical diagnosis of "other" Open wound
- Subject has a chronic open wound present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC
- Subject has a chronic open wound with a historical wound measurement showing less than 25% healing within 14 days prior to screening
- Subject has a chronic open wound with screening wound measurement showing less than 25% healing within 14 days prior to randomization
- Subject has an Open wound without infection or clinically visible exposed bone
- Index wound is a minimum of 0.5cm2 and a maximum of 25cm2 at first treatment visit
- Index ulcer has a maximum depth of 1cm at screening visit 1
- The chronic open wound is treated with offloading therapy, if applicable to location, while standing, sitting, and lying down for 14 days prior to randomization
- Adequate circulation of wounds located below the knee demonstrated by an ABI of >0.7 and <1.3, or TBI of >0.6 within 30 days prior to randomization OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to randomization.
- Index ulcer is free of infection prior to randomization and during screening phase.
- Index ulcer is free of necrotic debris prior to NeoThelium FT application
- Female subjects of childbearing potential having a negative pregnancy test prior to randomization
- Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.
- Subject is able and willing to follow the protocol requirements
- Subject had signed informed consent
- If 2 or more ulcers are present, the ulcers must be separated by at least 2 cm
Exclusion Criteria:
- Subject with a wound diagnosis of diabetic foot wound, pressure wound, venous leg wound, burn wound, or alternative diagnosis other than "open wound"
- Subject has a known life expectancy of <1 year
- Subject is unable to comply with protocol treatment
- Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing.
- Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
- Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
- Known contraindications to tissue-engineered allograft
- Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing
- Subject is pregnant or breastfeeding
- Subject with history of immunosuppressant treatment (systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the wound surface for >2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
- Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization
- Open wound with active infection
- Wound depth with visible exposed bone
- HBOT within 14 days prior to randomization
- Revascularization surgery on the index wound leg within 30 days of screening phase
- Index wound suspicious of neoplasm in the opinion of the principal investigator
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: No Intervention: Standard of Care
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
|
Experimental: Intervention: NeoThelium FT & Standard of Care
Wound cleansing, sharps debridement, NeoThelium FT application, Dressing for moisture balance, Offloading |
NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Complete Wound Closure
Prazo: 1-12 weeks
|
The primary endpoint will be the percentage of target ulcers that achieve complete wound closure. |
1-12 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage Wound Area Change
Prazo: 1-12 weeks
|
The percentage change in wound area from TV-1 to TV-13 will be measured weekly using digital photographic planimetry and physical examination. |
1-12 weeks
|
|
Pain Assessment
Prazo: Day 0, Day 14, Day 35, Day 56, Day 84
|
Change in pain associated with the target ulcer will be assessed using the Numeric Pain Rating Scale at designated time points |
Day 0, Day 14, Day 35, Day 56, Day 84
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Follow-Up Closure
Prazo: 2 weeks
|
Number of wounds remaining closed during the 2-week follow-up |
2 weeks
|
|
Adverse Events and Serious Adverse Events
Prazo: Day -14 through 91 days
|
The number and nature of adverse events (AEs) and series adverse events (SAEs) occurring during the study will be tracked and reported. |
Day -14 through 91 days
|
|
Time to Closure
Prazo: 1-12 weeks
|
Average number of grafts and/or weeks used to achieve wound closure |
1-12 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Angelina Ferguson, DNP, SygNola, LLC
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- HEAL
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .